Anhui Huaheng Biotechnology Co., Ltd. (SHA:688639)
38.19
+0.08 (0.21%)
At close: Jan 22, 2026
SHA:688639 Revenue
Anhui Huaheng Biotechnology had revenue of 704.38M CNY in the quarter ending September 30, 2025, with 34.73% growth. This brings the company's revenue in the last twelve months to 2.83B, up 34.04% year-over-year. In the year 2024, Anhui Huaheng Biotechnology had annual revenue of 2.18B with 12.37% growth.
Revenue (ttm)
2.83B
Revenue Growth
+34.04%
P/S Ratio
3.36
Revenue / Employee
1.29M
Employees
2,191
Market Cap
9.52B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.18B | 239.67M | 12.37% |
| Dec 31, 2023 | 1.94B | 519.62M | 36.63% |
| Dec 31, 2022 | 1.42B | 464.56M | 48.69% |
| Dec 31, 2021 | 954.10M | 466.85M | 95.81% |
| Dec 31, 2020 | 487.24M | -4.07M | -0.83% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.53B |
| Nanjing Vazyme Biotech | 1.34B |
| Chengdu Easton Biopharmaceuticals | 1.33B |
| Chengdu Kanghua Biological Products | 1.21B |
| Jiangxi Fushine Pharmaceutical | 970.32M |
| Bio-Thera Solutions | 845.32M |
| Acrobiosystems | 794.52M |
| Daan Gene | 765.48M |